ACRV

Acrivon Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth 6/10
  • Momentum 2/10
Acrivon Therapeutics sales and earnings growth
ACRV Growth
Good
  • Revenue Y/Y 0.00%
  • EPS Y/Y 21.77%
  • FCF Y/Y -6.74%
Acrivon Therapeutics gross and profit margin trends
ACRV Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC -69.00%
Acrivon Therapeutics net debt vs free cash flow
ACRV Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Acrivon Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗